Why Attend
Animal Health Innovation Asia is the premier B2B conference showcasing innovative technologies within the livestock, aquaculture and companion animal health markets. Last year, over 160 senior-level executives and influencers joined us to engage with the industry and discuss financial investment, M&A and market access into Asia.
Our 2017 event in Beijing had a special focus on China, with ten strategic partners from the region forming our Company Showcase - a chance for global companies to find new business partners from within China.
The Speakers for 2017
Joachim Hasenmaier
Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.
He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.
In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.
Juan Ramón Alaix
Juan Ramón Alaix is Chief Executive Officer of Zoetis. In this role, he leads the world’s leading animal health company with a singular focus on animal health medicines and vaccines, complemented by diagnostic products, genetic tests, biodevices and a range of services. In addition, he is a member of the Zoetis Board of Directors. Under his leadership, the company generated annual revenue of $4.9 billion in 2016 with approximately 9,000 employees worldwide.
Mr. Alaix has 35 years’ experience of increasing responsibility in finance, sales and management, including 20 years in the pharmaceutical industry. Prior to Zoetis, he served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Mr. Alaix joined Pfizer from Pharmacia in 2003 as regional president. In the 1990s, he served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country president of Spain for Pharmacia in 1998.
Dr. Tingwu Xue
Dr. XUE Tingwu is the President of China Animal Husbandry Group. He has been working for the company for over 30 years, with tremendous experience and knowledge in China’s agriculture industry, China’s animal husbandry industry, China’s animal health industry. He also is the pioneer who is dedicated to promote companies which serve safety agro-products and animal-related products to Chinese publics.
He is also actively engaged in various industry-related associations to fulfill his duty to the society. He is the key leading member of China Animal Agriculture Association, and vice-president of China Veterinary Drug Association, etc..
Plus, He is the founder and chairman of China Animal Health International Forum, which has been a platform to share information among animal health companies in order to promote the sustainable development of China animal health industry.
Dr. Zhao Yarong
Professor, Yarong ZHAO received Ph.D. in Veterinary Parasitology from China Agricultural University in 1993. With his cutting-edge researches in cryptosporidiosis, he received the First Grade Science & Technology Award from the Chinese Ministry of Agriculture in 1993.
From 1993 to 1998, he worked as National Technical Manager in Bayer Animal Health China. Later then in Fort Dodge Animal Health and Schering-Plough China as Regulatory and Technical Manager.
In 2003, he was appointed as General Manager of the Animal Medicine Research Center of the Dabeinong (DBN) Group, an innovative R&D center which focusing on animal infection disease diagnosis, animal biologic development and technology transfer. He has published over 50 scientific papers. Under his leadership, the Center has obtained Six National New Veterinary Drug Certificates and complete a number of technology transfer to other animal health companies with a total transaction value of approximately 350 million(RMB); Inactivated porcine circovirus type 2 (PCV2) vaccines, won the First Class State Science & Technology Progress Award in 2012.
Yongsheng Wang
Marc Prikazsky
Norman Lee
Norman Lee, Ph.D., Professor and founder of Tianjin Ringpu Bio-Technology Co. Ltd., Director of the MOA’s Key Laboratory for Veterinary Drug Innovation, Chairman of the National Veterinary Drug Industry Strategic Alliance for Technology and Innovation, Vice-President of the Chinese Veterinary Association, President of the Tianjin Veterinary Medicine Association, post-graduate advisor at the Tianjin Agricultural University. Dr. Lee has led over 21 national, provincial, and municipal science and technology projects. He was recipient of the second prize of the National Science and Technology Progress Award and twice of the first prize of the Tianjin Science and Technology Progress Award.
In 1998, Dr. Lee established Ringpu(Tianjin)Bio-Pharmacy Co. Ltd. And Ringpu (Baoding) Biological Pharmaceutical Co., Ltd. He also acted as General Manager of both companies.
In 2004, he was in charge of the research project: “Genetically engineering recombinant chicken α- interferon”. The project received the first prize of the Tianjin City Technology Innovation Award.
In 2008, he led a management team to restructure the company and established Tianjin Ringpu Bio-Technology Co. Ltd. He was appointed Acting Chairman of the Board.
On 17th September 2010, Tianjin Ringpu Bio-Technology Co. Ltd. was officially listed on the Shenzhen Stock Exchange and Dr. Lee is Chairman of the Board,
In 2012, Dr. Lee was part of the research team: “Swine and poultry pathogenic bacteria resistance research and its application in development of a safe and effective new veterinary drug”. The project received the second prize of the National Science and Technology Progress Award.
Ruiai Chen
Dr. Ruiai Chen received her Ph.D. in Microbiology from the China Agricultural University. Currently she is a professor and Ph.D. advisor at the College of Veterinary Medicines, South China Agricultural University.
Dr. Chen is President of Guangdong Wens Dahuanong Biotechnology Co., Ltd. (DHN), and Vice-Chairman of the China Veterinary Drug Association (CVDA). She is one of the most influential leaders in the Chinese animal health arena and, as a result, she is entitled to special allowances provided by the Chinese State Council, an honor for outstanding scientists in China. Dr. Chen is a well-known expert in the prevention and control of animal diseases, and vaccine research.
She possesses 41 patents and 22 new veterinary drug certificates. Dr. Chen has received 14 technical awards at the provincial and national levels, such as first prize for the Guangdong Provincial Science and Technology Award and the China Outstanding Patent. Her achievements include the development and industrialization of avian influenza vaccines, PRRS vaccines and coccidiosis vaccines. These vaccines are now making great contributions to disease control in China, Southeast Asia (e.g., Indonesia), and Middle East countries. Dr. Chen is also director of the Enterprise Key Laboratory of MOA for Animal Disease Prevention and Control, Biotechnology and Biological Product R&D. She has contributed greatly to commercialization of technology for animal vaccine and pharmaceutical products.
Dr. Tony Zi Long Tan
Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.
Dr. Tan received his veterinary degree from Foshan Veterinary College in China, his Master’s Degree in Animal Science from Alcorn State University, and his Ph.D. in Microbiology from Kansas State University. During his earlier research career, Dr. Tan helped develop several vaccines for cattle, dogs, and poultry. He has published over 50 scientific publications and research reports.
Dr. Tan served Intervet-Schering Plough (now Merck/MSD Animal Health) for over 15 years in different positions, including R&D Group Leader, Project Manager Vaccine Manufacturing, Technical Marketing Manager Aquatic Animals, and Business Unit Director Companion Animals China.
From 2009 to March 2016, Dr. Tan was Group Director of Business Development and Global Alliances for the Asia-Pacific Region of Zoetis (formerly Pfizer Animal Health). He successfully completed several large M&A transactions (total transaction value in excess of US$100 million) and a number of technology licensing deals. These include the first antitrust divesture project in China, the company’s first joint venture project for vaccine manufacturing, and divesture of a pharmaceutical manufacturing plant in Taiwan.
Dr. Tan is an Advisor to the China Global Investment & Trading Alliance (CGITA), an organization that promotes international business between China and other countries.
谭博士在动物保健领域从业超过30年，涉及各种动物品种和岗位部门，包括研发、产品注册、生产、市场、销售以及业务拓展。谭博士拥有丰富的国际工作经验，曾在美国、欧洲和亚洲（特别是中国）国家工作。谭博士是易联生物科技有限公司的创始人。易联生物科技是一家咨询公司帮助动保公司在新兴市场服的发展。
谭博士毕业于佛山兽医专科学校、从阿尔肯州立大学取得了动物科学的硕士学位、从堪萨斯州立大学取得了微生物学的博士学位。在他的研究生涯中，为牛、狗以及家禽类开发了数种疫苗，并且发表了超过50篇科学论文和研究报告。
谭博士在英特威/默沙东动物保健公司工作了超过15年，期间担任了不同职位，包括研发部主管、疫苗制造项目经理、水生动物的技术市场经理以及中国伴侣动物的事业部总监。
从2009年到2016年，谭博士在硕腾（原名辉瑞）担任业务拓展部门和国际联盟亚太地区高级总监。他成功地完成了数项重大企业并购交易（总交易额超过一亿美元）和若干技术转让项目。其中包括中国第一个反垄断剥离项目，辉瑞在中国的第一个合资企业和出售台湾的一家医药制造工厂。
此外，谭博士还是中国际投资和贸易联盟(CGITA)的顾问。CGITA是一个致力于促进中国和其他国家之间国际商务的组织。
Dirk Ehle
Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.
Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).
After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.
Dirk Ehle is married with three children.
Frank-Christian Raffel
Who You Will Meet
Attendees will represent the following key stakeholder groups in the Animal Health market
- Heads of Business Development, Animal Health, R&D from Multinational Pharmaceutical Companies
- CEOs, CSOs and Heads of Business Development from Emerging Animal Health Companies
- CEOs, Heads of Business Development, Product Discovery and Marketing from Incubators/ Accelerators, Contract Research Orgs, Consultants, Lawyers and other Service Providers
…all of the above with an interest in Livestock, Aquaculture and the Companion Animal markets
Attendees expected from the following key stakeholder groups and organizations
Key Content at the Forum
- Special Session with Chinese leadership: An opportunity for western companies to ask questions with regards regulatory hurdles in China and best practice for entering the market. Focus on innovation technology, problem solving and the international market chain.
- Company Showcase. Ten specially selected companies from China will pitch to the audience. These companies will be actively looking for financial investment or strategic partnerships.
- Keynote Talks from CEOs at leading multinational corporations including Boehringer Ingelheim, Zoetis and Bayer.
- Chinese Academic Professors. Special presentations from renowned academic leaders in China on state-of-the-art vaccine development.
Benefits of Attending
- Meet your next strategic animal health partner in China.
- Qualify the process for product registration, testing and approval.
- Discover how animal vaccine research is conducted in China.
- Attend the ONLY event of its kind in APAC. These two days provide unique access to acquisition and investment partners that would ordinarily take months.
In the News
We've been featured in Animal Pharm's news headlines!
Read what editor Joseph Harvey had to say by clicking on the image below:
Headline Partner
Associate Partners
Event Partners
Media Partners
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
The Agenda
Featured Speaker
Juan Ramón Alaix
Chief Executive Officer, Zoetis
Juan Ramón Alaix leads the world's leading animal health company with a singular focus on animal health medicines and vaccines, complemented by diagnostic products, genetic tests, biodevices and a range of services. In addition, he is a member of the Zoetis Board of Directors. Under his leadership, the company generated annual revenue of $4.9 billion in 2016 with approximately 9,000 employees worldwide.
Join him, as well as Chinese and Global industry leaders on-site this October to discuss the investment and M&A landscape in China, and importance of innovation for the future of animal health.
Download 2017 Agenda
Global Advisory Board
WHO THEY ARE
Each of our Advisory Board members have been chosen based on numerous recommendations, their deep knowledge and Industry experience and ability to provide a clear vision, not just for their own organizations, but for the industry as a whole.
WHY THEY ARE HERE
Board members guide not just content, but also the underlying mission of the events to drive positive change.
Aaron Schacht
Jean Deleforge
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
George Gunn
Linda Rhodes
Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.
Joachim Hasenmaier
Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.
He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.
In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.
Clinton Lewis
Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.
Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.
In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).
Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.
Mr. Jishu Shi
Dirk Ehle
Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.
Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).
After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.
Dirk Ehle is married with three children.
Selection Committee
Dr. Tony Zi Long Tan
Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.
Dr. Tan received his veterinary degree from Foshan Veterinary College in China, his Master’s Degree in Animal Science from Alcorn State University, and his Ph.D. in Microbiology from Kansas State University. During his earlier research career, Dr. Tan helped develop several vaccines for cattle, dogs, and poultry. He has published over 50 scientific publications and research reports.
Dr. Tan served Intervet-Schering Plough (now Merck/MSD Animal Health) for over 15 years in different positions, including R&D Group Leader, Project Manager Vaccine Manufacturing, Technical Marketing Manager Aquatic Animals, and Business Unit Director Companion Animals China.
From 2009 to March 2016, Dr. Tan was Group Director of Business Development and Global Alliances for the Asia-Pacific Region of Zoetis (formerly Pfizer Animal Health). He successfully completed several large M&A transactions (total transaction value in excess of US$100 million) and a number of technology licensing deals. These include the first antitrust divesture project in China, the company’s first joint venture project for vaccine manufacturing, and divesture of a pharmaceutical manufacturing plant in Taiwan.
Dr. Tan is an Advisor to the China Global Investment & Trading Alliance (CGITA), an organization that promotes international business between China and other countries.
谭博士在动物保健领域从业超过30年，涉及各种动物品种和岗位部门，包括研发、产品注册、生产、市场、销售以及业务拓展。谭博士拥有丰富的国际工作经验，曾在美国、欧洲和亚洲（特别是中国）国家工作。谭博士是易联生物科技有限公司的创始人。易联生物科技是一家咨询公司帮助动保公司在新兴市场服的发展。
谭博士毕业于佛山兽医专科学校、从阿尔肯州立大学取得了动物科学的硕士学位、从堪萨斯州立大学取得了微生物学的博士学位。在他的研究生涯中，为牛、狗以及家禽类开发了数种疫苗，并且发表了超过50篇科学论文和研究报告。
谭博士在英特威/默沙东动物保健公司工作了超过15年，期间担任了不同职位，包括研发部主管、疫苗制造项目经理、水生动物的技术市场经理以及中国伴侣动物的事业部总监。
从2009年到2016年，谭博士在硕腾（原名辉瑞）担任业务拓展部门和国际联盟亚太地区高级总监。他成功地完成了数项重大企业并购交易（总交易额超过一亿美元）和若干技术转让项目。其中包括中国第一个反垄断剥离项目，辉瑞在中国的第一个合资企业和出售台湾的一家医药制造工厂。
此外，谭博士还是中国际投资和贸易联盟(CGITA)的顾问。CGITA是一个致力于促进中国和其他国家之间国际商务的组织。
Candy Cheng
Mark Engel
Randolph Seidler
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
